Skip to main content
Premium Trial:

Request an Annual Quote

Power3, Biosite to Develop Protein Biomarker-based Diagnostics

NEW YORK, July 12 (GenomeWeb News) - Proteomic tool shop Power3 Medical Products will give Biosite access to certain of its protein biomarker antibody targets and intellectual property as part of an alliance to evaluate and develop diagnostic tests, the companies said today.

Terms of the agreement call for Biosite to develop and commercialize all potential immunodiagnostic tests based on the Power3 biomarker antibody targets it licensed from the company.

Power3's IP portfolio includes pending patents, provisional patent applications, and research and license agreements with medical research institutions in the areas of cancer, drug resistance, neurodegenerative disease, and metabolic syndrome, the company said.

The financial terms of the agreement were not disclosed.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.